对于低前切除综合征 (LARS) 的Ondansetron:一项双盲,安慰剂控制,交叉,随机化研究
Sotirios Georgios Popeskou1, Raffaello Roesel1, Seraina Faes2
1Department of Visceral Surgery, Hospital of Lugano (EOC), Lugano, Switzerland.
Annals of surgery
|July 12, 2023
概括
丹塞有效治疗前下切除综合征 (LARS),通过显著降低LARS得分和改善生活质量. 这种安全而简单的治疗方法为治疗直肠外科手术后LARS症状提供了一个有希望的选择.
科学领域:
- 胃肠病学 胃肠病学
- 结肠直肠手术 结肠直肠手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 低前切除综合征 (LARS) 是直肠切除手术后的常见和衰弱的并发症.
- 目前的LARS管理策略的有效性有限,需要新的治疗方法.
研究的目的:
- 评估选择性血清素5-HT3受体对抗剂Ondansetron在治疗LARS患者中的疗效和安全性.
- 评估丹塞对LARS症状严重程度,失禁和生活质量的影响.
主要方法:
- 采用了一个随机的,多中心的,双盲的,安慰剂控制的,交叉研究设计.
- 患有LARS (LARS评分>20) 的患者接受了为期4周的丹塞治疗,随后接受了4周的安慰剂治疗,或者反之亦然.
- LARS严重程度 (LARS评分),失禁 (Vaizey评分) 和生活质量 (IBS-QoL) 是主要和次要终点.
主要成果:
- 与安慰剂相比,Ondansetron治疗导致平均LARS得分显著减少25%.
- 在Ondansetron治疗期间,严重LARS患者的比例显著下降,从88%降至41%.
- 随着Ondansetron的使用,LARS得分,失禁和生活质量得到了持续的改善.
结论:
- 丹塞显示出良好的安全性,并且有效缓解LARS症状.
- 这项研究表明,丹塞作为一种有价值的治疗选择,可以改善LARS患者的症状和生活质量.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
249
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
249
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
346
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
346
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
204
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
204
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
405
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
405
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
313
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
313


